A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors

PURPOSE: Ridaforolimus (AP23573, MK-8669 or deforolimus) is an inhibitor of mammalian target of rapamycin (mTOR), an important regulator in the cell survival pathway. This open-label, single center phase I study aimed to investigate the pharmacokinetic (PK) and safety profiles of ridaforolimus in Ch...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Liu, Lian, Zhang, Wen, Li, Wenhua, Lv, Fangfang, Xia, Zuguang, Zhang, Sheng, Liu, Wen, Zandvliet, Anthe S, Waajen, Sylvia, Zhang, Li Xin, Yan, Li, Li, Jin
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2013
Soggetti:
Rapid Communication
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3716995/
https://ncbi.nlm.nih.gov/pubmed/23829943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-6-48
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi